OR WAIT 15 SECS
The company will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France.
Sanofi announced on June 16, 2020 that it will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France.
According to a company press release, the Evolutive Vaccine Facility (EVF) in Neuville sur Saône, France, will feature several fully digital production modules that will have the ability to produce three to four vaccines simultaneously. Sanofi will invest EUR 490 million (USD$548 million) into the site over five years and is expected to create 200 new jobs.
Additionally, the company plans to invest EUR120 million (USD$134 million) into a new R&D center at its site in Marcy-l'Etoile, France, the press release said. The new facility will include specialized laboratories for the development of vaccines for emerging diseases and pandemic risks.
“By investing in a new industrial site and a R&D center, Sanofi positions France at the core of its strategy, aiming to make France a world-class center of excellence in vaccine research and production," said Paul Hudson, CEO at Sanofi, in the press release. “Sanofi is a major healthcare player in France, in Europe, and worldwide. It is our responsibility to focus our resources and expertise against the current pandemic, but also to invest in preparing for future ones. We welcome the ongoing collaboration and commitment of the French authorities who we have been working alongside with the last several months to achieve this.”